Full Width Image Background
Full Width Image Background
Text

There are three ways to send us a prescription

Download, complete and sign the necessary therapy enrollment form. Be sure to note Optum Frontier Therapies as your preferred pharmacy.

Find forms

Full Width Image Background
Text

Option 1: e-prescribe

Frontier Therapies II - Optum
6425 Santa Margarita St. #110
Las Vegas, NV 89118

NABP: 788638
NPI: 1720364532
NCPDP: 2992750

Full Width Image Background
Text

Option 2: fax

Send the appropriate therapy forms and documentation to 1-866-991-9929.
 



 

Full Width Image Background
Text

Option 3: call

Discuss the process, understand how to submit documentation, or place an order by calling us at 1-855-768-9727.



 

Text

  

Text

Therapies and forms

 

Find out more about the therapies we dispense below. Select Find forms to access the appropriate therapy enrollment forms and documentation.

A

ADSTILADRIN

ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

B

BEQVEZTM

BEQVEZ (fidanacogene elaparvovec) is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of adults with moderately-severe to severe hemophilia B (congenital factor IX deficiency) with factor IX activity less than or equal to 2 IU/dL (International units per deciliter) without antibodies to AAV serotype Rh74 (AAVRh74).

Bylvay™

Bylvay is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC).

Find forms

E

ELEVIDYS™

ELEVIDYS (delandistrogene moxeparvovec-rokl) is an adeno-associated virus vector-based gene therapy indicated for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. ELEVIDYS is a registered trademark of Sarepta Therapeutics, Inc.

Find forms

F

FILSPARI®

FILSPARI (sparsentan) is an endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ration (UPCR) ≥1.5 g/g.

Find forms

K

Kuvan™

Kuvan is a phenylalanine hydroxylase activator indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.

Find forms

L

LUMRYZ™

LUMRYZ is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.

Find forms

N

NITYR®

NITYR® is a hydroxyphenyl-pyruvate dioxygenase inhibitor used to treat adults and children with hereditary tyrosinemia type 1 (HT-1). NITYR works by preventing the body from breaking down an amino acid called tyrosine and by keeping other toxic substances from building up and causing harm to liver or kidneys. 

Find forms

P

Palynziq™

Palynziq is a phenylalanine (Phe)-metabolizing enzyme indicated to reduce blood Phe concentrations in adult patients with phenylketonuria who have uncontrolled blood Phe concentrations greater than 600 micromol/L on existing management.

Find forms

Q

QalsodyTM

QALSODYTM (tofersen) is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).

Find forms

R

REBYOTA

REBYOTA™ is a novel first-in-class microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.

Find forms

ROCTAVIAN™

ROCTAVIAN is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity < 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test.

Find forms

S

Sucraid®

Sucraid® is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).

Find forms

V

VOXZOGO™

VOXZOGO™ is a C type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses.

Find forms